Lanreotide
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Lanreotide is a somatostatin analog that inhibits growth hormone and other hormones. It is approved for treatment of neuroendocrine tumors and acromegaly, making it relevant for multiple endocrine neoplasia syndromes. The drug provides sustained hormone suppression with monthly or extended dosing intervals.
Indications & Therapeutic Use
Acromegaly, gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome, multiple endocrine neoplasia
Linked Diseases:
multiple endocrine neoplasia
D44.8D009377
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Lanreotide — GNH India
122 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Inj. LANREOTIDE Acetate
120mginjectionUSA
Ipstyl
EU
Ipstyl Autogel
EU
Lanrenet
EU
Lanreotid Amdipharm
EU
Lanreotid Pharmathen
EU
Lanreotid Sun
EU
Lanreotid Viatris
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Lanreotide
| Generic Name | Lanreotide |
| Brands | 1 brand available |
| Active Ingredient | Lanreotide acetate |
| Drug Class | Acromegaly |
| Manufacturer | Ipsen |
| Dosage Forms | Subcutaneous injection, 60mg, 90mg, 120mg prefilled syringe |
| Medical Code | H01CB03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00353496 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes